Antimalarial Drug Resistance Dynamics and Pharmacology

Malaria remains a major global health challenge, driven by the emergence and spread of resistance to frontline therapies. The dynamics of antimalarial drug resistance are shaped by parasite biology, host immunity, treatment practices and drug properties. Resistance arises through genetic mutations in Plasmodium species that reduce drug efficacy, often facilitated by suboptimal dosing, incomplete treatment courses and high parasite burdens. Pharmacological principles—pharmacokinetics and pharmacodynamics—govern the concentration–time profile of antimalarial compounds in the body and their parasite-killing activity. A detailed understanding of drug absorption, distribution, metabolism and elimination enables optimisation of dosing regimens to suppress resistant strains. Computational models of parasite evolution, coupled with in vivo and in vitro experiments, illuminate the interplay between within-host competition, transmission potential and selective pressure on resistant parasites. Contemporary research emphasises combination therapies to reduce the chance of de novo resistance, multistage drug candidates to interrupt both blood and liver stages of Plasmodium, and innovative delivery systems to improve adherence and extend prophylactic cover. The integration of target-based drug discovery, phenotypic screening and molecular surveillance underpins efforts to extend the useful therapeutic life of existing drugs and to identify novel chemotypes capable of overcoming resistant parasites.

Research from Nature Portfolio

Recent studies have demonstrated that combining artemisinin derivatives with two partner drugs in triple artemisinin-based combination therapies significantly delays the emergence and spread of artemisinin resistance. Individual-based modelling of Plasmodium falciparum transmission and evolution predicts that early adoption of these triple therapies can reduce treatment failure rates and prolong the efficacy of current regimens in regions with multidrug resistance. In parallel, development of long-acting injectable formulations of atovaquone solid-drug nanoparticles has shown sustained prophylactic plasma concentrations for at least one month following a single dose. This approach targets liver-stage parasites, offers causal protection against infection and may translate into a practical tool for travellers and endemic‐area control programmes by mitigating issues of poor adherence and rapid elimination of conventional oral formulations.

Antimalarial Drug Resistance Dynamics and Pharmacology publication trend

The graph below shows the total number of articles in antimalarial drug resistance dynamics and pharmacology across all publications each year (not limited to Nature Index journals).

Technical terms

Artemisinin: A sesquiterpene lactone antimalarial derived from Artemisia annua, acting rapidly against blood-stage parasites.

Triple artemisinin-based combination therapy (TACT): A regimen combining an artemisinin derivative with two partner drugs to prevent resistance emergence.

Pharmacokinetics: The study of drug absorption, distribution, metabolism and excretion.

Pharmacodynamics: The relationship between drug concentration and its biological effect on the parasite.

Electron transport chain (ETC): A series of mitochondrial protein complexes that generate ATP and serve as antimalarial targets.

Recrudescence: The recurrence of parasitaemia after treatment due to survival of resistant parasites.

References

1. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nature Communications (2023).
2. Pyrimidine Azepine Targets the Plasmodium bc 1 Complex and Displays Multistage Antimalarial Activity. JACS Au (2024).
3. Advances in malaria pharmacology and the online guide to MALARIA PHARMACOLOGY: IUPHAR review 38. British Journal of Pharmacology (2023).
4. A screen of drug-like molecules identifies chemically diverse electron transport chain inhibitors in apicomplexan parasites. PLOS Pathogens (2023).
5. Promising antimalarial hits from phenotypic screens: a review of recently-described multi-stage actives and their modes of action. Frontiers in Cellular and Infection Microbiology (2023).
6. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malaria Journal (2009).
7. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nature Communications (2018).
8. Within-host competition and drug resistance in the human malaria parasite Plasmodium falciparum. Proceedings of the Royal Society B (2016).